Virtu KCG Holdings LLC Acquires 53,215 Shares of Arrowhead Pharmaceuticals, Inc. (ARWR)

Virtu KCG Holdings LLC boosted its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 115.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 99,267 shares of the biotechnology company’s stock after acquiring an additional 53,215 shares during the quarter. Virtu KCG Holdings LLC owned 0.13% of Arrowhead Pharmaceuticals worth $161,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. UBS Asset Management Americas Inc. lifted its position in Arrowhead Pharmaceuticals by 414.7% in the 1st quarter. UBS Asset Management Americas Inc. now owns 66,400 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 53,500 shares in the last quarter. SG Americas Securities LLC lifted its position in Arrowhead Pharmaceuticals by 287.9% in the 1st quarter. SG Americas Securities LLC now owns 100,747 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 74,776 shares in the last quarter. Wells Fargo & Company MN lifted its position in Arrowhead Pharmaceuticals by 144.8% in the 1st quarter. Wells Fargo & Company MN now owns 150,346 shares of the biotechnology company’s stock valued at $278,000 after acquiring an additional 88,933 shares in the last quarter. LMR Partners LLP bought a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at about $467,000. Finally, Bank of New York Mellon Corp lifted its position in Arrowhead Pharmaceuticals by 3.7% in the 1st quarter. Bank of New York Mellon Corp now owns 314,034 shares of the biotechnology company’s stock valued at $581,000 after acquiring an additional 11,099 shares in the last quarter. 20.62% of the stock is currently owned by institutional investors and hedge funds.

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ ARWR) opened at 3.65 on Tuesday. The firm has a 50-day moving average of $3.83 and a 200 day moving average of $2.33. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $1.20 and a 1-year high of $6.18. The stock’s market cap is $272.92 million.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.06. The firm had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. Equities research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post ($0.42) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Virtu KCG Holdings LLC Acquires 53,215 Shares of Arrowhead Pharmaceuticals, Inc. (ARWR)” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/10/31/virtu-kcg-holdings-llc-acquires-53215-shares-of-arrowhead-pharmaceuticals-inc-arwr.html.

ARWR has been the topic of several recent research reports. ValuEngine cut shares of Arrowhead Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. William Blair raised shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, September 18th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $2.00 price target (up previously from $1.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, September 15th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $2.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, July 28th. Finally, Chardan Capital reaffirmed a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $2.00.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.

Institutional Ownership by Quarter for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

What are top analysts saying about Arrowhead Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Arrowhead Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit